Phimosis Incidence among Users of SGLT2i Compared with GLP-1RA: Evidence from Denmark

Abstract

Nationwide registry data from Denmark indicate a low but notable risk of phimosis in male patients prescribed SGLT2 inhibitors compared to GLP-1 receptor agonists. Adjusted hazard ratios suggest a small relative risk increase, although confounding by indication cannot be excluded. Further pharmacoepidemiological studies are required to validate these signals and guide clinical decision-making.